US Patent

US9890141 — Crystalline pharmaceutical and methods of preparation and use thereof

Composition of Matter · Assigned to Sarcode Bioscience Inc · Expires 2030-10-21 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel crystalline polymorphic forms of a compound that inhibits LFA-1.

USPTO Abstract

Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

Drugs covered by this patent

Patent Metadata

Patent number
US9890141
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-10-21
Drug substance claim
Yes
Drug product claim
No
Assignee
Sarcode Bioscience Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.